[1]刘旭,王霞,何媛.糖尿病视网膜病变危险因素与预防研究进展[J].眼科新进展,2018,38(7):687-691.[doi:10.13389/j.cnki.rao.2018.0162]
　LIU Xu,WANG Xia,HE Yuan.The research progress of risk factors and prevention in diabetic retinopathy[J].Recent Advances in Ophthalmology,2018,38(7):687-691.[doi:10.13389/j.cnki.rao.2018.0162]
点击复制

糖尿病视网膜病变危险因素与预防研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年7期
页码:
687-691
栏目:
文献综述
出版日期:
2018-07-05

文章信息/Info

Title:
The research progress of risk factors and prevention in diabetic retinopathy
作者:
刘旭; 王霞; 何媛
710038　陕西省西安市，西安医学院第二附属医院
Author(s):
LIU Xu; WANG Xia; HE Yuan
Second Affiliated Hospital of Xi’an Medical University，Xi’an 710038，Shaanxi Province，China
关键词:
糖尿病视网膜病变; 危险因素; 预防
Keywords:
diabetic retinopathy; risk factor; prevention
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0162
文献标志码:
A
摘要:
糖尿病视网膜病变（diabetic retinopathy，DR）是糖尿病（diabetes mellitus，DM）的常见慢性并发症之一，属于微血管病变，是工作人群及中老年人视力减退甚至导致失明的主要原因。1/3~1/2的糖尿病患者同时伴有视网膜病变，DR与糖尿病病程、高血糖、高血压及高血脂等危险因素均密切相关。个体血糖和血压的最优控制仍然是预防DR发生和阻止病变进展的基石，抗血管内皮因子治疗被认为是目前最有效的糖尿病性黄斑水肿的治疗方案。这些有效的防治手段，患者及医生意识的提高，定期筛查DR，将有效改善DR患者的预后，减少因DR导致失明患者的人数，进一步提高患者的生存质量。
Abstract:
Diabetic retinopathy （DR） is one of the common chronic complications of diabetes mellitus （DM）.It belongs to microangiopathy and it is the leading cause of vision loss and even blindness in the working population and middle-aged and elderly people.About one-third to one-half of the diabetic patients was accompanied by retinopathy.DR is closely linked to the risk factors such as diabetic duration，hyperglycemia，hypertension，and hyperlipidemia and so on.The optimal control of individual blood glucose and blood pressure remains the cornerstone for preventing the development of DR and preventing the progression of the disease.Anti-vascular endothelium treatment is considered to be the most effective treatment for diabetic macular edema.These effective methods of prevention，improvement of patient and doctor awareness，and regular screening of DR will effectively improve the prognosis of patients with DR，reduce the number of patients with blindness caused by DR，and further improve the quality of life of patients.

参考文献/References:

［1］　FEDERATION I D.Diabetes Facts and Figures［OL］.2015.
［2］　WHITING D R，GUARIGUATA L，WEIL C，SHAW J.IDF Diabetes Atlas：Global estimates of the prevalence of diabetes for 2011 and 2030［J］.Diabetes Res Clin Pract，2011，94（3）：311-321.
［3］　CHINESE MEDICAL ASSOCIATION OPHTHALMOLOGICAL SOCIETY EYE FUNDOLOGY GROUP.Guide for Clinical Diagnosis and Treatment of Diabetes Retinopathy in China（2014）［J］.Chin J Ophthalmol，2014，50（11）：851-865.
中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南（2014年）.中华眼科杂志 2014，50（11）：851-865.
［4］　LIU Y，SONG Y，TAO L，QIU W，LV H，JIANG X，et al.Prevalence of diabetic retinopathy among 13473 patients with diabetes mellitus in China：a cross-sectional epidemiological survey in six provinces［J］.BMJ Open，2017，7（1）：e013199.
［5］　DEHGHAN M H，KATIBEH M，AHMADIEH H，NOURINIA R，YASERI M.Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd，Iran：The Yazd Eye Study［J］.J Diabetes，2015，7（1）：139-141.
［6］　GILOYAN A，HARUTYUNYAN T，PETROSYAN V.The prevalence of and major risk factors associated with diabetic retinopathy in Gegharkunik province of Armenia：cross-sectional study［J］.BMC Ophthalmol，2015，15（1）：1-7.
［7］　KAI S，SARNGAL S，GANJOO S.To study the prevalence of diabetic retinopathy in diabetes mellitus patients and its correlation with various associated risk factors［J］.J Evolut Med Dental Sci，2015，4（98）：16341-16346.
［8］　HU Y，TENG W，LIU L，CHEN K，LIU L，HUA R，et al.Prevalence and risk factors of diabetes and diabetic retinopathy in Liaoning Province，China：A population-based cross-sectional study［J］.PLoS One，2015，10（3）：e0121477.
［9］　CLELAND C R，BURTON M J，CLAUDETTE H，ANTHONY H，PAUL C，MAKUPA W U，et al.Diabetic retinopathy in tanzania：prevalence and risk factors at entry into a regional screening programme［J］.Trop Med Inter Heal，2016，21（3）：417-426.
［10］　FORGA L，GOI M J，IBEZ B，CAMBRA K，GARCA-MOURIZ M，IRIARTE A.Influence of age at diagnosis and time-dependent risk factors on the development of diabetic retinopathy in patients with type 1 diabetes［J］.J Diabetes Res，2016，2016：1-7.
［11］　KEEL S，ITSIOPOULOS C，KOKLANIS K，VUKICEVIC M，CAMERON F，BRAZIONIS L.Prevalence and risk factors for diabetic retinopathy in a hospital-based population of Australian children and adolescents with type 1 diabetes［J］.J Pediatric Endocrinol Metabol Jpem，2016，29（10）：1135-1142.
［12］　TING D S，CHEUNG G C，WONG T Y.Diabetic retinopathy：global prevalence，major risk factors，screening practices and public health challenges：a review［J］.Clin Exp Ophthalmol，2016，44（4）：260-277.
［13］　YUN J S，LIM T S，CHA S A，AHN Y B，SONG K H，CHOI J A，et al.Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in korea［J］.Diabetes Metabol J，2016，40（6）：482-493.
［14］　YUN K J，KIM H J，KIM M K，KWON H S，BAEK K H，ROH Y J，et al.Risk factors for the development and progression of diabetic kidney disease in patients with type 2 diabetes mellitus and advanced diabetic retinopathy［J］.Diabetes Metabol J，2016，40（6）：473-481.
［15］　KLEIN R，KLEIN B E，MOSS S E，DAVIS M D，DEMETS D L.The wisconsin epidemiologic study of diabetic retinopathy.Ⅱ.Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years［J］.Arch Ophthalmol，1984，102（4）：527.
［16］　LIU L，WU J，YUE S，GENG J，LIAN J，TENG W，et al.Incidence density and risk factors of diabetic retinopathy within type 2 diabetes：A five-year cohort study in China （Report 1） ［J］.Int J Env Res Pub Heal，2015，12（7）：7899-7909.
［17］　ARNDT C，LECLERCQ I，NAZEYROLLAS P，DURLACH A，DUCASSE A，MOVESAYAN I，et al.Association of endothelial lipase Thr111Ile polymorphism with proliferative retinopathy in type 2 diabetes patients［J］.Diabetes Metabol，2014，40（6）：452-458.
［18］　BHARGAVA M，CHEUNG C Y，SABANAYAGAM C，HUANG L，LAMOUREUX E L，WANG J J，et al.Prevalence and risk factors for retinopathy in persons without diabetes：the Singapore Indian Eye Study［J］.Acta Ophthalmol，2014，92（8）：602-609.
［19］　KYARI F，TAFIDA A，SIVASUBRAMANIAM S，MURTHY G V，PETO T，GILBERT C E.Prevalence and risk factors for diabetes and diabetic retinopathy：results from the Nigeria national blindness and visual impairment survey［J］.BMC Public Health，2014，14（1）：1-12.
［20］　AL-RUBEAAN K，YOUSSEF A M，SUBHANI S N，AHMAD N A，AL-SHARQAWI A H，AL-MUTLAQ H M，et al.Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic：a Saudi National Diabetes Registry-based study［J］.PLoS One，2015，93（2）：140-147.
［21］　WANG N K，LAI C C，WANG J P，WU W C，LIU L，YEH L K，et al.Risk factors associated with the development of retinopathy 10?yr after the diagnosis of juvenile-onset type 1 diabetes in Taiwan：a cohort study from the CGJDES［J］.Pediatric Diabetes，2016，17（6）：407.
［22］　HAMMES H P，WELP R，KEMPE H P，WAGNER C，SIEGEL E，HOLL R W.Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database［J］.PLoS One，2015，10（7）：e0132492.
［23］　XIANG N Z，HENG C K，TAJUNISAH I，RANI K U.Soluble Receptor for Advanced Glycation End-Product （sRAGE）/Pentosidine Ratio：A Potential Risk Factor Determinant for Type 2 Diabetic Retinopathy［J］.Inter J Molecular Sci，2013，14（4）：7480-7491.
［24］　CHIANG P P，LAMOUREUX E L，ZHENG Y，TAY W T，MITCHELL P，WANG J J，et al.Frequency and risk factors of non-retinopathy ocular conditions in people with diabetes：the Singapore Malay Eye Study［J］.Diabet Med，2013，30（2）：e32-e40.
［25］　ZHANG H Y，WANG J Y，YING G S，SHEN L P，ZHANG Z.Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients［J］.J Zhejiang Univ-Sci B（Biomed Biotechnol），2013，14（5）：392-399.
［26］　LS L，TY W.Lipids and diabetic retinopathy［J］.Expert Opin Biol Ther，2012，12（1）：93-105.
［27］　ABOUGALAMBOU S S I，ABOUGALAMBOU A S.Risk factors associated with diabetic retinopathy among type 2 diabetes patients at teaching hospital in Malaysia［J］.Diabetes Met Syndrome Clin Res Rev，2015，9（2）：98-103.
［28］　SASONGKO M B，WONG T Y，NGUYEN T T，KAWASAKI R，JENKINS A，SHAW J，et al.Serum Apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids［J］.Diabetes Care，2011，34（2）：474-479.
［29］　SASONGKO M B，WONG T Y，NGUYEN T T，SHAW J E，JENKINS A J，WANG J J.Novel versus traditional risk markers for diabetic retinopathy［J］.Diabetologia，2012，55（3）：666-670.
［30］　ALSHABRAWEY M，ZHANG W，MCDONALD D.Diabetic retinopathy：mechanism，diagnosis，prevention，and treatment［J］.Biomed Res Int，2015，2015：854593.
［31］　CHU L，WANG B，XU B，DONG N.Aqueous cytokines as predictors of macular edema in non-diabetic patients following uncomplicated phacoemulsification cataract surgery［J］.Biomed Res Int，2015，2015（12）：126984.
［32］　PARK J H，KIM J E，GU J Y，YOO H J，PARK S H，KIM Y I，et al.Evaluation of circulating markers of neutrophil extracellular Trap （NET） formation as risk factors for diabetic retinopathy in a case-control association study［J］.Exp Clin Endocrinol Diabetes，2016，124（09）：557-561.
［33］　HUANG H，HE J，DA’KUAWN J，WEI Y，LIU Y，WANG S，et al.Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition［J］.Diabetes，2015，64（1）：200-212.
［34］　BEHL T，KOTWANI A.Exploring the various aspects of the pathological role of vascular endothelial growth factor （VEGF） in diabetic retinopathy［J］.Pharmacol Res，2015，99：137.
［35］　BERTELSEN G，PETO T，LINDEKLEIV H，SCHIRMER H，SOLBU M D，TOFT I，et al.Sex differences in risk factors for retinopathy in non-diabetic men and women：the Troms Eye Study［J］.Acta Ophthalmol，2014，92（4）：316-322.
［36］　GAEDT T M，BORG M M，GREEN A，SJLIE A K，GRAUSLUND J.Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes［J］?Ophthalmologica，2013，230（1）：50-54.
［37］　SNJEANA K，MARTINA T，ANTONELA G A，SPOMENKA L，JASMINKA S R，MIRELA K.Body mass index.A risk factor for retinopathy in type 2 diabetic patients［J］.Mediators Inflam，2013，2013（4）：436329.
［38］　MEHTA M，MEHTA S，PATHAK P，CHAWLA A.A study of pattern of diabetic retinopathy and associated risk factors in diabetic patients：a hospital based study［J］.J Evolution Med Dental Sci，2015，4（89）：15388-15391.
［39］　CHANDRAKUMAR S V，THIYAGARAJAN P，AMIT J K，MURUGALAKSHMI T，MURALIKRISHNAN S.A case control study to evaluate thyroid dysfunction as a risk factor for diabetic retinopathy in type 2 diabetes mellitus［J］.J Evolution Med Dental Sci，2016，5（72）：5253-5256.
［40］　HIETATA K，FORSBLOM C，SUMMANEN P，GROUP P H.Heritability of proliferative diabetic retinopathy［J］.Diabetes，2008，57（8）：2176-2180.
［41］　HUANG Y C，LIN J M，LIN H J，CHEN C C，CHEN S Y，TSAI C H，et al.Genome-wide association study of diabetic retinopathy in a Taiwanese population［J］.Ophthalmology，2011，118（4）：642-648.
［42］　MATHEWSON P A，SHARMA H E，HELEN P，PETER S，PETER N，TSALOUMAS M D，DENNISTON A K.Social deprivation as a risk factor for late presentation of proliferative diabetic retinopathy［J］.Clin Ophthalmol，2015，2015（default）：347-352.
［43］　MPHIL S L，PRADEEP RAMULU M D，LAMOUREUX E L，CHARUMATHI SABANAYAGAM M D.Addressing risk factors，screening，and preventative treatment for diabetic retinopathy in developing countries：a review［J］.Clin Exp Ophthalmol，2016，44（4）：300-320.
［44］　DIRANI M，CROWSTON J G，VAN W P.Physical inactivity as a risk factor for diabetic retinopathy? A review［J］.Clin Exp Ophthalmol，2014，42（6）：574-581.
［45］　DUBE L，VAN D B S，HOUSIAUX M，DHOORE W，RENDALL-MKOSI K.Type 2 diabetes self-management education programs in high and low mortality developing countries：a systematic review［J］.Diabetes Educator，2015，41（1）：69.
［46］　STEEL D H，SMITH J M.Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy［J］.Cochr Database Sys Rev，2011，8（5）：688-694.
［47］　CHEUNG N，WONG I Y，WONG T Y.Ocular anti-VEGF therapy for diabetic retinopathy：overview of clinical efficacy and evolving applications［J］.Diabetes Care，2014，37（4）：900-905.
［48］　HE J，WANG H，LIU Y，LI W，KIM D，HUANG H.Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy［J］.J Ophthalmol，2015，2015（13）：605946.
［49］　MORGAN C L，OWENS D R，AUBONNET P，CARR E S M，JENKINSJONES S，POOLE C D，et al.Primary prevention of diabetic retinopathy with fibrates：a retrospective，matched cohort study［J］.BMJ Open，2013，3（12）：e004025.
［50］　MORAES G D.Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy［J］.Clin Exp Ophthalmol，2016，44（9）：838-852.
［51］　BEHL T，KOTWANI A.Omega-3 fatty acids in prevention of diabetic retinopathy［J］.J Pharm Pharmacol，2017，69（8）.
［52］　TIKHONENKO M，LYDIC T A，OPREANU M，CALZI S L，BOZACK S，MCSORLEY K M，et al.N-3 Polyunsaturated fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function［J］.PLoS One，2013，8（1）：e55177.
［53］　ZKIRIS A，ERKILI K，KO A，MISTIK.Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy［J］.British J Ophthalmol，2007，91（1）：69-73.
［54］　EZQUER F，EZQUER M，ARANGO-RODRIGUEZ M，CONGET P.Could donor multipotent mesenchymal stromal cells prevent or delay the onset of diabetic retinopathy［J］?Acta Ophthalmol，2013，92（2）：e86-e95.
［55］　MOTTAGHI S，LARIJANI B，SHARIFI A M.Atorvastatin：an efficient step forward in mesenchymal stem cell therapy of diabetic retinopathy［J］.Cytotherapy，2013，15（3）：263-266.
［56］　CAHOON J M，RAI R R，CARROLL L S，UEHARA H，ZHANG X，O’NEIL C L，et al.Intravitreal AAV2.COMP-Ang1 prevents neurovascular degeneration in a murine model of diabetic retinopathy［J］.Diabetes，2015，64（12）：4247.
［57］　YU Z，GONG C，LU B，YANG L，SHENG Y，JI L，et al.Dendrobium chrysotoxum Lindl.Alleviates diabetic retinopathy by preventing retinal inflammation and tight junction protein decrease［J］.J Diabetes Res，2015，2015：518317.
［58］　SEN S，CHEN S，WU Y，FENG B，LUI E K，CHAKRABARTI S.Preventive effects of North American ginseng （Panax quinquefolius） on diabetic retinopathy and cardiomyopathy［J］.Phytother Res，2013，27（2）：290.
［59］　GAO D，GUO Y，LI X，LI X，LI Z，XUE M，et al.An aqueous extract of radix astragali，angelica sinensis，and panax notoginseng is effective in preventing diabetic retinopathy［J］.Evid Based Compl Alternat Med，2013，2013（2013）：578165.
［60］　CHEN W，YAO X，ZHOU C，ZHANG Z，GUI G，LIN B.Danhong huayu koufuye prevents diabetic retinopathy in streptozotocin-induced diabetic rats via antioxidation and anti-inflammation［J］.Med Inflam，2017，2017（98）：3059763.
［61］　THIRAPHATTHANAVONG P，WATTANATHORN J，MUCHIMAPURA S，THUKHAMMEE W，LERTRAT K，SURIHARN B.The combined extract of purple waxy corn and ginger prevents cataractogenesis and retinopathy in streptozotocin-diabetic rats［J］.Oxid Med Cell Long，2014，2014：789406.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]边领斋 刘巨平 魏瑞华 李筱荣 赵少贞 华宁 王铁成 李颖 任新军 梁娟 邹媛媛 赵小云 刘文洁.云南省高海拔农村多民族聚居区年龄相关性白内障危险因素调查[J].眼科新进展,2013,33(1):000.
[5]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[6]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[7]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[8]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[9]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[10]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[11]崔颖 郭海科 韩云飞 孟倩丽 张良 尹东明.2型糖尿病住院患者糖尿病视网膜病变患病率及危险因素分析[J].眼科新进展,2012,32(8):000.
[12]吴京阳,刘磊,耿金,等.eGFR作为糖尿病视网膜病变预警因子的研究[J].眼科新进展,2014,34(8):740.[doi:10.13389/j.cnki.rao.2014.0203]
　WU Jing-Yang,LIU Lei,GENG Jin,et al.Study on estimated GFR as predictor of DR[J].Recent Advances in Ophthalmology,2014,34(7):740.[doi:10.13389/j.cnki.rao.2014.0203]
[13]李涛,吴小利,刘兴德,等.糖尿病视网膜病变与外周血管和心血管病变的相关性研究[J].眼科新进展,2020,40(2):173.[doi:10.13389/j.cnki.rao.2020.0041]
　LI Tao,WU Xiaoli,LIU Xingde,et al.Correlation of diabetic retinopathy with peripheral vascular disease and cardiovascular disease[J].Recent Advances in Ophthalmology,2020,40(7):173.[doi:10.13389/j.cnki.rao.2020.0041]
[14]万光明,薛瑢.糖尿病视网膜病变的危险因素与预防控制[J].眼科新进展,2021,41(6):501.[doi:10.13389/j.cnki.rao.2021.0104]
　WAN Guangming,XUE Rong.Risk factors for diabetic retinopathy and its prevention and treatment[J].Recent Advances in Ophthalmology,2021,41(7):501.[doi:10.13389/j.cnki.rao.2021.0104]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81100665、81770929）
更新日期/Last Update: 2018-07-12